Bluejay Diagnostics (NASDAQ: BJDX) reported third-quarter 2026 progress in clinical development, manufacturing and regulatory preparation for its Symphony IL-6 platform. The company completed enrollment in its SYMON-II clinical validation study and is targeting an FDA 510(k) submission in the first half of 2027.
As of September 30, 2026, Bluejay had $7.38 million in cash and cash equivalents. The company said existing cash resources are estimated to support operations through the second quarter of 2027, while additional financing will be required for longer-term development and commercialization plans.
- SYMON-II enrollment was completed with 777 evaluable patients, exceeding the original target of 750 patients.
- A preliminary baseline analysis identified 140 deaths within 28 days, representing about 18% mortality.
- Bluejay established an alternative Symphony cartridge manufacturing site through Sanyoseiko before its October 23, 2026 contractual deadline.
- Net cash used in operating activities was approximately $5.09 million for the nine months ended September 30, 2026.
- The Symphony IL-6 Test has not been cleared or approved by the FDA and is not available for commercial clinical use in the United States.
$BJDX Insider Trading Activity
$BJDX insiders have traded $BJDX stock on the open market 2 times in the past 6 months. Of those trades, 1 have been purchases and 1 have been sales.
Here’s a breakdown of recent trading of $BJDX stock by insiders over the last 6 months:
- FINANCIAL LP HRT has made 1 purchase buying 64,047 shares for an estimated $96,710 and 1 sale selling 34,938 shares for an estimated $48,913.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$BJDX Hedge Fund Activity
We have seen 11 institutional investors add shares of $BJDX stock to their portfolio, and 1 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- ARMISTICE CAPITAL, LLC added 131,000 shares (+inf%) to their portfolio in Q2 2026, for an estimated $157,200
- HEIGHTS CAPITAL MANAGEMENT, INC added 35,400 shares (+inf%) to their portfolio in Q2 2026, for an estimated $42,480
- SABBY MANAGEMENT, LLC removed 28,726 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $137,884
- BOOTHBAY FUND MANAGEMENT, LLC added 27,130 shares (+inf%) to their portfolio in Q2 2026, for an estimated $32,556
- JANE STREET GROUP, LLC added 10,974 shares (+inf%) to their portfolio in Q3 2026, for an estimated $37,526
- BANK OF AMERICA CORP /DE/ added 10,337 shares (+inf%) to their portfolio in Q2 2026, for an estimated $12,404
- GEODE CAPITAL MANAGEMENT, LLC added 9,901 shares (+inf%) to their portfolio in Q3 2026, for an estimated $33,857
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
